RemeMG Study
Are you living with Myasthenia Gravis (MG)?
The RemeMG study is testing a study drug called telitacicept to see how safe and effective it might be in adults living with generalized MG.
You may be eligible to join if you:
- Are 18 years or older
- Have been diagnosed with gMG
- Do not have any other autoimmune diseases, like rheumatoid arthritis or Sjogren’s syndrome
If you qualify, you will have a 50% chance of receiving either the study drug (telitacicept) or placebo for 24 weeks of treatment. Both are taken as weekly injections, some of which may be self-injected at home between study visits. You can choose to do the injection at home or at our study site.
After the first 24-week treatment period is completed, you will have the option to take part in a 48-week extension treatment period where everyone will receive the study drug.
If you are interested in learning more, please email ResearchNCNE@myneurodr.com / call 781-551-5812 opt.2.